{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:45:04Z","timestamp":1787067904675,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.psychres.2023.115349","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T01:16:49Z","timestamp":1690075009000},"page":"115349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis"],"prefix":"10.1016","volume":"327","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-7566","authenticated-orcid":false,"given":"Otto","family":"Simonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Carlbring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2023.115349_bib0001","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","article-title":"Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects","volume":"4","author":"Aday","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.psychres.2023.115349_bib0002","first-page":"221","article-title":"Effect sizes for continuous data","volume":"2","author":"Borenstein","year":"2009","journal-title":"Handb. Res. Synth. Meta-Anal."},{"issue":"5","key":"10.1016\/j.psychres.2023.115349_bib0003","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ","volume":"36","author":"Burke","year":"2017","journal-title":"Stat. Med."},{"issue":"7","key":"10.1016\/j.psychres.2023.115349_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2023.115349_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"issue":"15","key":"10.1016\/j.psychres.2023.115349_bib0006","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2023.115349_bib0022","series-title":"R: A language and Environment for Statistical Computing","author":"Core Team","year":"2022"},{"issue":"5","key":"10.1016\/j.psychres.2023.115349_bib0007","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1017\/S2045796015000864","article-title":"How to prove that your therapy is effective, even when it is not: a guideline","volume":"25","author":"Cuijpers","year":"2016","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1","key":"10.1016\/j.psychres.2023.115349_bib0008","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/wps.20701","article-title":"A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression","volume":"19","author":"Cuijpers","year":"2020","journal-title":"World Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2023.115349_bib0009","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2215-0366(20)30036-5","article-title":"Treatment outcomes for depression: challenges and opportunities","volume":"7","author":"Cuijpers","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2023.115349_bib0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/da.22249","article-title":"What is the threshold for a clinically relevant effect? The case of major depressive disorders","volume":"31","author":"Cuijpers","year":"2014","journal-title":"Depress. Anxiety"},{"issue":"5","key":"10.1016\/j.psychres.2023.115349_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2023.115349_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.psychres.2023.115349_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/acps.12275","article-title":"Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis","volume":"130","author":"Furukawa","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2023.115349_bib0014","unstructured":"Heinze, G., Ploner, M., Jiricka, L. (2022). logistf: firth's bias-reduced logistic regression. R package Version 1.24.1, <https:\/\/CRAN.R-project.org\/package=logistf>."},{"key":"10.1016\/j.psychres.2023.115349_bib0015","article-title":"A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders","author":"Kisely","year":"2022","journal-title":"Austr. N. Z. J. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115349_bib0016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jad.2016.12.013","article-title":"The effect of treatment as usual on major depressive disorder: a meta-analysis","volume":"210","author":"Kolovos","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.psychres.2023.115349_bib0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/02698811211044688","article-title":"Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis","volume":"36","author":"Leger","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2023.115349_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","article-title":"Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis","volume":"296","author":"Li","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.psychres.2023.115349_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08039488.2015.1028438","article-title":"Deteriorated and unchanged patients in psychological treatment in Swedish primary care and psychiatry","volume":"70","author":"Mechler","year":"2016","journal-title":"Nord. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2023.115349_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2023.115349_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2023.115349_bib0023","article-title":"Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials","volume":"8","author":"Roscoe","year":"2022","journal-title":"Drug Sci., Policy aLaw,"},{"issue":"5","key":"10.1016\/j.psychres.2023.115349_bib0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry,"},{"issue":"2","key":"10.1016\/j.psychres.2023.115349_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1037\/ccp0000158","article-title":"For better or worse: an individual patient data meta-analysis of deterioration among participants receiving Internet-based cognitive behavior therapy","volume":"85","author":"Rozental","year":"2017","journal-title":"J. Consult. Clin. Psychol."},{"issue":"16","key":"10.1016\/j.psychres.2023.115349_bib0026","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.psychres.2023.115349_bib0027","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/jcm11040938","article-title":"Trajectory of antidepressant effects after single-or two-dose administration of psilocybin: a systematic review and multivariate meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.psychres.2023.115349_bib0028","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/YIC.0b013e3282f948f5","article-title":"The GRID-HAMD: standardization of the Hamilton depression rating scale","volume":"23","author":"Williams","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2023.115349_bib0029","doi-asserted-by":"crossref","first-page":"39235","DOI":"10.4088\/JCP.21r14057","article-title":"Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials","volume":"83","author":"Zeifman","year":"2022","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178123002998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178123002998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T16:25:15Z","timestamp":1717604715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178123002998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S0165178123002998"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2023.115349","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2023.115349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115349"}}